Permanent record · RIR–2039
Integrating Microbiome-Targeted Interventions into Clinical Management Protocols for Chronic Kidney Disease Patients
This research explores the gut–kidney axis to identify novel therapeutic targets for chronic kidney disease. It evaluates the efficacy of microbiome-based interventions like prebiotics and synbiotics in clinical settings.
Can microbiome-targeted interventions effectively modulate harmful metabolites to improve clinical outcomes in chronic kidney disease patients?
Knowledge gap
What remains worth asking
The source suggests that the gut–kidney axis is a promising therapeutic target; it remains useful to test the clinical efficacy of specific synbiotic interventions in controlled trials.
Potential contribution
Why it may matter
Targeting the microbiome may provide a novel, non-invasive approach to managing chronic kidney disease progression.
Academic placement
OECD fields and topic tags
Scope: Patients with stage 3-4 chronic kidney disease. · Method signals: Clinical Trial, Multi-omics Analysis, Systematic Review
Possible study pathways
One question, different levels
Translational research in microbiome-based therapeutic interventions.
Mechanistic investigation of the gut-kidney axis and clinical trial design.
Qualification signal
85/100
- Requires clinical trial infrastructure.
- High ethical requirements for patient intervention studies.
- Open-access scholarly source and DOI metadata verified
Provenance
Research Idea Registry curation
- DOI and bibliographic metadata independently resolved
- Open-access status verified
- The accessible abstract explicitly states the future-research direction
APA 7 source
Alobaidi, S. (2025). The gut–kidney axis in chronic kidney disease: mechanisms, microbial metabolites, and microbiome-targeted therapeutics. Frontiers in Medicine, 12, Article 1675458. https://doi.org/10.3389/fmed.2025.1675458
Abstract (explicit future-research recommendation)
Open source ↗